|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.94 CHF | +1.81% |
|
+4.64% | +4.80% |
| 03:33pm | Corporate results bound the become the next catalyst for markets |  |
| 03:21pm | Dpa-AFX Overview: COMPANIES from 23.04.2024 - 15:15 | DP |
ZURICH, Aug 15 (Reuters) - Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial.
The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said. (Reporting by John Revill; Editing by Christian Schmollinger)
| 1st Jan change | Capi. | |
|---|---|---|
| +4.80% | 210B | |
| +27.32% | 659B | |
| +27.68% | 557B | |
| -4.52% | 359B | |
| +16.57% | 322B | |
| +9.43% | 297B | |
| +6.30% | 215B | |
| -6.05% | 200B | |
| -8.42% | 149B | |
| -4.98% | 146B |
NOVARTIS AG 
